Nadia Waheed, M.D., is a renowned ophthalmologist and retina specialist with more than two decades of experience in clinical practice, research, and drug development. She earned her medical degree from Aga Khan University Medical College in Pakistan, followed by residency training in internal medicine at Pennsylvania Hospital and ophthalmology at Tufts Medical Center/New England Eye Center. Dr. Waheed completed advanced fellowships in medical retina and ocular imaging at Tufts and vitreoretinal surgery at William Beaumont Hospital, establishing her as a leader in retinal disease management. Her career is marked by significant achievements, including over 250 peer-reviewed publications, editorial roles for journals like *Retina* and *Ophthalmology Retina*, and pivotal contributions to clinical trials for anti-VEGF therapies, gene therapies, and advanced imaging modalities. As Director of the Noninvasive Imaging Lab at Tufts, she pioneered multimodal imaging techniques for early detection of age-related macular degeneration, diabetic retinopathy, and other chorioretinal conditions, influencing global standards in ophthalmic care. Currently serving as Chief Medical Officer at Ocular Therapeutix Inc., Dr. Waheed oversees the company's clinical development pipeline, including sustained-release drug delivery platforms like DEXTENZA for post-surgical inflammation and pain, and investigational therapies such as OTX-TKI for wet AMD. Her strategic leadership has accelerated Phase 2 and 3 trials, fostering partnerships with regulatory bodies and advancing innovative treatments to improve vision preservation and patient quality of life.